pentobarbital will lessen the extent or result of fedratinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Keep away from or Use Alternate Drug. Influence of coadministering a strong CYP3A4 inducer with fedratinib has not been analyzed.

Reserve concomitant prescribing of those drugs in patients for whom other cure alternatives are insufficient. Restrict dosages and durations to the least necessary. Watch closely for signs of respiratory depression and sedation.

pentobarbital will decrease the level or effect of docetaxel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Small/Significance Unidentified.

pentobarbital will lessen the extent or impact of elbasvir/grazoprevir by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. The therapeutic influence of elbasvir/grazoprevir may very well be diminished if coadministered with robust CYP3A inducers and is therefore contraindicated.

pentobarbital will decrease the level or effect of ondansetron by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch. No dosage adjustment for ondansetron is recommended for people on these drugs.

Contraindicated (one)pentobarbital will minimize the level or effect of lumacaftor/ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

pentobarbital will reduce the level or effect of propafenone by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Minimal/Significance Unfamiliar.

pentobarbital will lower the level or result of lumacaftor/ivacaftor by impacting hepatic/intestinal enzyme CYP3A4 more info metabolism. Contraindicated.

pentobarbital will decrease the level or impact of nelfinavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.

pentobarbital will reduce the level or effect of celecoxib by affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Importance Unknown.

Observe Intently (two)pentobarbital will lower the extent or impact of buprenorphine, long-performing injection by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Intently. People who transfer to buprenorphine extensive-acting injection from transmucosal buprenorphine coadministered with CYP3A4 inducers must be monitored to guarantee buprenorphine plasma concentrations are suitable.

pentobarbital will decrease the extent or effect of dexamethasone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Check.

Contraindicated (one)pentobarbital will lower the level or impact of naloxegol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Use of naloxegol with strong CYP3A4 inducers is not suggested

pentobarbital will lessen the level or impact of lorlatinib by impacting hepatic/intestinal enzyme CYP3A4 metabolism.